Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers
Authors:
- 1 December 2022
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 79 (12) , 1312-1318
Abstract
Importance: Clinical trial activity in amyotrophic lateral sclerosis (ALS) is dramatically increasing; as a result, trial modifications have been introduced to improve efficiency, outcome measures have been reassessed, and considerable discussion about the level of data necessary to advance a drug to approval has occurred. This review discusses what recent pivotal studies can teach the community about these topics.Observations: By restricting inclusion and exclusion criteria, recent trials have enrolled populations distinct from previous studies. This has led to efficacy signals being observed in studies that are smaller and shorter than was thought feasible previously. However, such trials raise questions about generalizability of results. Small trials with equivocal clinical results also raise questions about the data necessary to lead to regulatory approval. The ALS Functional Rating Scale–Revised remains the most commonly used primary outcome measure; this review discusses innovations in its use. Blood neurofilament levels can predict prognosis in ALS and may be a sensitive indicator of biologic effect; current knowledge does not yet support its use as a primary outcome.Conclusions and Relevance: It is now possible to use specific inclusion criteria to recruit a homogeneous patient population progressing at a specific rate; this will likely impact trials in the future. Generalizability of results on limited populations remains a concern. Although clinical outcomes remain the most appropriate primary outcome measures, fluid markers reflecting biologically important processes will assume more importance as more is learned about the association between such markers and clinical end points. The benefit of use of analytic strategies, such as responder analyses, is still uncertain.Keywords
This publication has 47 references indexed in Scilit:
- Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trialThe Lancet Neurology, 2013
- A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral SclerosisPLOS ONE, 2012
- Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trialThe Lancet Neurology, 2010
- Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trialAmyotrophic Lateral Sclerosis, 2009
- Subcutaneous IGF-1 is not beneficial in 2-year ALS trialNeurology, 2008
- Creatine monohydrate in ALS: Effects on strength, fatigue, respiratory status and ALSFRSAmyotrophic Lateral Sclerosis, 2008
- Phase II/III randomized trial of TCH346 in patients with ALSNeurology, 2007
- High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind studyJournal of Neural Transmission, 2004
- Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trialsAmyotrophic Lateral Sclerosis, 2004
- Xaliproden in amyotrophic lateral sclerosis: early clinical trialsAmyotrophic Lateral Sclerosis, 2004